2024
Risk Score for Hepatocellular Cancer in Adults Without Viral Hepatitis or Cirrhosis
Ilagan-Ying Y, Gordon K, Tate J, Lim J, Torgersen J, Re V, Justice A, Taddei T. Risk Score for Hepatocellular Cancer in Adults Without Viral Hepatitis or Cirrhosis. JAMA Network Open 2024, 7: e2443608. PMID: 39504020, PMCID: PMC11541635, DOI: 10.1001/jamanetworkopen.2024.43608.Peer-Reviewed Original ResearchConceptsClassification of DiseasesBody mass indexRisk scoreNinth Revision and International Statistical Classification of DiseasesMass indexAlcohol useInternational Statistical Classification of DiseasesStatistical Classification of DiseasesElectronic health recordsNon-Hispanic blacksInternational Classification of DiseasesNon-Hispanic whitesClinical Modification diagnosisHepatocellular carcinoma risk scoreRisk of hepatocellular carcinomaCox proportional hazards regression modelsValidation sampleHigh-risk individualsProportional hazards regression modelsHCC risk factorsFIB-4Multivariate risk scoreHepatocellular carcinomaHazards regression modelsViral hepatitisIdentification of hepatic steatosis among persons with and without HIV using natural language processing
Torgersen J, Skanderson M, Kidwai-Khan F, Carbonari D, Tate J, Park L, Bhattacharya D, Lim J, Taddei T, Justice A, Re V. Identification of hepatic steatosis among persons with and without HIV using natural language processing. Hepatology Communications 2024, 8: e0468. PMID: 38896066, PMCID: PMC11186806, DOI: 10.1097/hc9.0000000000000468.Peer-Reviewed Original ResearchConceptsImaging ReportingSteatotic liver diseaseHIV statusHepatic steatosisPrevalence of metabolic comorbiditiesImaging studiesVeterans Aging Cohort StudyCompare patient characteristicsPositive predictive valueAlcohol use disorderAging Cohort StudyIdentification of hepatic steatosisHIV infectionHepatitis BMetabolic comorbiditiesNatural language processing algorithmsRadiological studiesCohort studyPatient characteristicsClinical reviewLiver diseaseHIVPredictive valueUse disorderClinical image reportsAn explainable machine learning model for prediction of high-risk nonalcoholic steatohepatitis
Njei B, Osta E, Njei N, Al-Ajlouni Y, Lim J. An explainable machine learning model for prediction of high-risk nonalcoholic steatohepatitis. Scientific Reports 2024, 14: 8589. PMID: 38615137, PMCID: PMC11016071, DOI: 10.1038/s41598-024-59183-4.Peer-Reviewed Original ResearchConceptsNational Health and Nutrition Examination SurveyRisk of progression to cirrhosisClinical risk indexHealth and Nutrition Examination SurveyControlled attenuation parameter valuesNovel therapeutic optionsLiver stiffness measurementProgression to cirrhosisAspartate aminotransferase levelsNutrition Examination SurveyResource-limited settingsFIB-4Fibrosis scorePlatelet countAminotransferase levelsTherapeutic optionsWaist circumferenceClinically applicable modelExamination SurveyNonalcoholic steatohepatitisFAST scoreEarly identificationElastography measurementsStiffness measurementPatients
2023
Prevalence and characteristics of hepatitis delta virus infection in patients with hepatitis B in the United States: An analysis of the All-Payer Claims Database
Gish R, Jacobson I, Lim J, Waters-Banker C, Kaushik A, Kim C, Cyhaniuk A, Wong R. Prevalence and characteristics of hepatitis delta virus infection in patients with hepatitis B in the United States: An analysis of the All-Payer Claims Database. Hepatology 2023, 79: 1117-1128. PMID: 37976395, PMCID: PMC11020024, DOI: 10.1097/hep.0000000000000687.Peer-Reviewed Original ResearchConceptsHBV/HDV infectionLiver complicationsAll-Payer Claims DatabaseClaims databaseRisk of liver-related morbidityHepatitis delta virus infectionPrevalence of HDVDelta virus infectionProportion of patientsTime of diagnosisLiver-related morbidityUS insured populationHDV prevalenceHBV populationsHIV infectionCompensated cirrhosisDecompensated cirrhosisHBV infectionDelayed diagnosisHDV infectionHepatitis BViral hepatitisHBV/HDVPatient characteristicsSevere formPrecipitous changes in nomenclature and definitions—NAFLD becomes SLD: Implications for and expectations of AASLD journals
Malhi H, Brown R, Lim J, Reau N, Tapper E, Wong C, Gores G. Precipitous changes in nomenclature and definitions—NAFLD becomes SLD: Implications for and expectations of AASLD journals. Hepatology Communications 2023, 7: e0318. PMID: 37941420, PMCID: PMC10635597, DOI: 10.1097/hc9.0000000000000318.Peer-Reviewed Original ResearchPrecipitous changes in nomenclature and definitions—NAFLD becomes SLD: Implications for and expectations of AASLD journals
Malhi H, Brown R, Lim J, Reau N, Tapper E, Wong C, Gores G. Precipitous changes in nomenclature and definitions—NAFLD becomes SLD: Implications for and expectations of AASLD journals. Hepatology 2023, 78: 1680-1681. PMID: 37941421, DOI: 10.1097/hep.0000000000000619.Peer-Reviewed Original ResearchScreening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice
Ilagan-Ying Y, Banini B, Do A, Lam R, Lim J. Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice. Current Gastroenterology Reports 2023, 25: 213-224. PMID: 37768417, DOI: 10.1007/s11894-023-00883-8.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNon-alcoholic fatty liver diseaseNon-invasive testsFatty liver diseaseLiver diseaseCommon chronic liver diseaseNonalcoholic fatty liver diseaseCurrent expert guidelinesHigh-risk patientsChronic liver diseaseSteatotic liver diseaseClinical practice implicationsHepatic decompensationLiver biopsySociety guidelinesSpecialty referralsNovel therapiesExpert guidelinesLiver cancerDisease awarenessObesity epidemicSerum indicesClinical practiceScreening toolDiseaseDiagnosisExercise Does Not Independently Improve Histological Outcomes in Biopsy-Proven Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
Chen G, Banini B, Do A, Gunderson C, Zaman S, Lim J. Exercise Does Not Independently Improve Histological Outcomes in Biopsy-Proven Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Genes 2023, 14: 1811. PMID: 37761951, PMCID: PMC10531443, DOI: 10.3390/genes14091811.Peer-Reviewed Original ResearchConceptsNon-alcoholic fatty liver diseaseBiopsy-proven non-alcoholic fatty liver diseaseEffects of exerciseFatty liver diseaseHistological outcomesLiver histologyLiver diseaseClinical trialsHistological endpointsSystematic reviewSignificant histopathological improvementNAFLD activity scoreImpact of exerciseIndependent effectsRandom-effects modelSystematic literature searchHistopathological improvementExercise interventionActivity scoreClinical endpointsPooled estimatesMeta-AnalysisTotal participantsLiterature searchComparison groupHepatitis B care cascade among people with HIV/HBV coinfection in the North American AIDS Cohort Collaboration on Research and Design, 2012–2016
Kim J, Newcomb C, Carbonari D, Torgersen J, Althoff K, Kitahata M, Klein M, Moore R, Reddy K, Silverberg M, Mayor A, Horberg M, Cachay E, Lim J, Gill M, Chew K, Sterling T, Hull M, Seaberg E, Kirk G, Coburn S, Lang R, McGinnis K, Gebo K, Napravnik S, Kim H, Re V, Research and Design of IeDEA F. Hepatitis B care cascade among people with HIV/HBV coinfection in the North American AIDS Cohort Collaboration on Research and Design, 2012–2016. PLOS ONE 2023, 18: e0290889. PMID: 37656704, PMCID: PMC10473492, DOI: 10.1371/journal.pone.0290889.Peer-Reviewed Original ResearchConceptsNorth American AIDS Cohort CollaborationUndetectable HBV DNAHBV coinfectionHBV DNACare cascadeCohort CollaborationViral suppressionHIV/HBV coinfectionTenofovir-based antiretroviral therapyHIV/HBVAntiretroviral therapy regimenCross-sectional studyDelivery of careHBV therapyHBV treatmentHBV viremiaAntiretroviral therapyHBV infectionHIV infectionTherapy regimenChronic infectionClinical cohortCoinfectionTherapyInfectionLean NAFLD is associated with adverse liver events and mortality: Moving beyond BMI
Do A, Lim J. Lean NAFLD is associated with adverse liver events and mortality: Moving beyond BMI. Hepatology 2023, 78: 6-7. PMID: 36896961, DOI: 10.1097/hep.0000000000000360.Peer-Reviewed Original Research
2022
The Independent Effect of Exercise on Biopsy-Proven Non-Alcoholic Fatty Liver Disease: A Systematic Review
Chen G, Banini B, Do A, Lim J. The Independent Effect of Exercise on Biopsy-Proven Non-Alcoholic Fatty Liver Disease: A Systematic Review. Clinical And Molecular Hepatology 2022, 29: s319-s332. PMID: 36517000, PMCID: PMC10029942, DOI: 10.3350/cmh.2022.0366.Peer-Reviewed Original ResearchConceptsNon-alcoholic fatty liver diseaseBiopsy-proven non-alcoholic fatty liver diseaseNon-invasive testsFatty liver diseaseHepatic steatosisLiver fibrosisLiver diseaseHistological endpointsIndependent effectsSystematic reviewNon-randomized interventional studyMagnetic resonance imaging-based techniquesAdditional large RCTsChronic liver diseaseSignificant histological improvementEffects of exerciseClinical outcome endpointsSystematic literature searchHistological improvementExercise interventionHepatocyte ballooningOriginal research studiesLarge RCTsOutcome endpointsInterventional studyAssociation Between Alcohol Use Disorder and Receipt of Direct-Acting Antiviral Hepatitis C Virus Treatment
Haque L, Fiellin D, Tate J, Esserman D, Bhattacharya D, Butt A, Crystal S, Edelman E, Gordon A, Lim J, Tetrault J, Williams E, Bryant K, Cartwright E, Rentsch C, Justice A, Re V, McGinnis K. Association Between Alcohol Use Disorder and Receipt of Direct-Acting Antiviral Hepatitis C Virus Treatment. JAMA Network Open 2022, 5: e2246604. PMID: 36515952, PMCID: PMC9856353, DOI: 10.1001/jamanetworkopen.2022.46604.Peer-Reviewed Original ResearchConceptsCurrent alcohol use disorderLow-risk drinkingAlcohol use disorderVeterans Health AdministrationHistory of AUDDAA treatmentAlcohol use categoriesAUD historyCohort studyRisk drinkingUse disordersDirect acting antiviral (DAA) treatmentAlcohol Use Disorders Identification Test-Consumption (AUDIT-C) questionnaireHepatitis C virus infectionHepatitis C virus (HCV) treatmentCox proportional hazards regressionC virus infectionC virus treatmentProportional hazards regressionTenth Revision diagnosisAUDIT-C questionnaireInternational Statistical ClassificationRelated Health ProblemsAntiviral treatmentRevision diagnosisAGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review
Long MT, Noureddin M, Lim JK. AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review. Gastroenterology 2022, 163: 764-774.e1. PMID: 35842345, PMCID: PMC9398982, DOI: 10.1053/j.gastro.2022.06.023.Peer-Reviewed Original ResearchConceptsLean Nonalcoholic Fatty Liver DiseaseNonalcoholic fatty liver diseaseType 2 diabetes mellitusClinical Practice Updates CommitteeBiopsy-confirmed nonalcoholic steatohepatitisFatty liver diseaseBody mass indexDiabetes mellitusLean individualsLiver diseaseNonalcoholic steatohepatitisLean personsLiver cirrhosisMass indexHepatic steatosisNoninvasive testsManagement of NAFLDSodium-glucose cotransporter 2 inhibitorsGlucagon-like peptide-1 agonistsLysosomal acid lipase deficiencyPrognosis of NAFLDAGA Governing BoardLiver biochemical testsModest weight lossCotransporter 2 inhibitors
2020
Abnormal Liver Tests in COVID‐19: A Retrospective Observational Cohort Study of 1,827 Patients in a Major U.S. Hospital Network
Hundt MA, Deng Y, Ciarleglio MM, Nathanson MH, Lim JK. Abnormal Liver Tests in COVID‐19: A Retrospective Observational Cohort Study of 1,827 Patients in a Major U.S. Hospital Network. Hepatology 2020, 72: 1169-1176. PMID: 32725890, PMCID: PMC9258788, DOI: 10.1002/hep.31487.Peer-Reviewed Original ResearchConceptsAbnormal liver testsLiver testsCohort studyClinical outcomesCOVID-19Yale New Haven Health SystemCoronavirus-19 disease (COVID-19) pandemicSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virusRetrospective observational cohort studyAcute respiratory distress syndromeRetrospective cohort studyLiver test abnormalitiesObservational cohort studySevere COVID-19Liver transaminase elevationsRespiratory distress syndromeBody mass indexPoor clinical outcomeCoronavirus 2 virusCOVID-19 treatmentNonpulmonary manifestationsPeak hospitalizationsICU admissionMultiorgan failureTransaminase elevationAGA Institute Rapid Review and Recommendations on the Role of Pre-Procedure SARS-CoV-2 Testing and Endoscopy
Sultan S, Siddique SM, Altayar O, Caliendo AM, Davitkov P, Feuerstein JD, Francis D, Inadomi J, Lim JK, Falck-Ytter Y, Mustafa RA, Association A. AGA Institute Rapid Review and Recommendations on the Role of Pre-Procedure SARS-CoV-2 Testing and Endoscopy. Gastroenterology 2020, 159: 1935-1948.e5. PMID: 32735862, PMCID: PMC7386603, DOI: 10.1053/j.gastro.2020.07.043.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, ViralAsymptomatic InfectionsBetacoronavirusClinical Laboratory TechniquesCommunicable Disease ControlCoronavirus InfectionsCOVID-19COVID-19 TestingEndoscopyGastroenterologyHumansInfectious Disease Transmission, Patient-to-ProfessionalPandemicsPersonal Protective EquipmentPneumonia, ViralPractice Guidelines as TopicPredictive Value of TestsPreoperative CarePrevalenceRNA, ViralSARS-CoV-2Societies, MedicalUnited StatesPrevalence of Chronic Hepatitis B Virus Infection in the United States.
Lim JK, Nguyen MH, Kim WR, Gish R, Perumalswami P, Jacobson IM. Prevalence of Chronic Hepatitis B Virus Infection in the United States. The American Journal Of Gastroenterology 2020, 115: 1429-1438. PMID: 32483003, DOI: 10.14309/ajg.0000000000000651.Peer-Reviewed Original ResearchConceptsChronic hepatitis B virus infectionHepatitis B virus infectionB virus infectionWorld Health OrganizationChronic HBVVirus infectionMajor global health problemChronic HBV infectionGlobal health problemHBV prevalenceHBV infectionHBV screeningLiver cirrhosisSubstantial morbidityLiver diseaseClinical complicationsHepatocellular carcinomaHealth problemsElimination planPrevalenceDisease FoundationHealth OrganizationInfectionPeer-reviewed literatureUnited StatesAGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19
Sultan S, Altayar O, Siddique SM, Davitkov P, Feuerstein JD, Lim JK, Falck-Ytter Y, El-Serag HB, . AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19. Gastroenterology 2020, 159: 320-334.e27. PMID: 32407808, PMCID: PMC7212965, DOI: 10.1053/j.gastro.2020.05.001.Peer-Reviewed Original ResearchMeSH KeywordsAntiviral AgentsBetacoronavirusClinical Laboratory TechniquesCoronavirus InfectionsCOVID-19COVID-19 TestingGastroenterologyGastrointestinal DiseasesGastrointestinal TractHumansLiverLiver DiseasesLiver Function TestsPandemicsPneumonia, ViralPractice Guidelines as TopicPrevalenceReferral and ConsultationSARS-CoV-2Societies, MedicalUnited StatesConceptsNausea/vomitingPooled prevalence estimatesAbdominal painLiver manifestationsGI symptomsLiver abnormalitiesCOVID-19Prevalence estimatesPractice statementsGI symptom questionnaireLiver enzyme abnormalitiesCertainty of evidencePrevalence of diarrheaCoronavirus disease 2019Best practice statementsSystematic literature searchStudy selection processFixed-effects modelNausea/Gastrointestinal symptomsLiver functionUnique patientsGRADE frameworkSubgroup analysisSymptom questionnaireAGA Rapid Recommendations for Gastrointestinal Procedures During the COVID-19 Pandemic
Sultan S, Lim JK, Altayar O, Davitkov P, Feuerstein JD, Siddique SM, Falck-Ytter Y, El-Serag HB, Institute A. AGA Rapid Recommendations for Gastrointestinal Procedures During the COVID-19 Pandemic. Gastroenterology 2020, 159: 739-758.e4. PMID: 32247018, PMCID: PMC7118600, DOI: 10.1053/j.gastro.2020.03.072.Peer-Reviewed Original Research
2018
Healthcare resource utilization and costs by disease severity in an insured national sample of US patients with chronic hepatitis B
Nguyen MH, Ozbay AB, Liou I, Meyer N, Gordon SC, Dusheiko G, Lim JK. Healthcare resource utilization and costs by disease severity in an insured national sample of US patients with chronic hepatitis B. Journal Of Hepatology 2018, 70: 24-32. PMID: 30287341, DOI: 10.1016/j.jhep.2018.09.021.Peer-Reviewed Original ResearchConceptsAdvanced liver diseaseCompensated liver diseaseLiver diseaseDisease severityCause inpatientLiver transplantHepatitis BHealthcare utilizationHepatocellular carcinomaHigh emergency department (ED) utilizationHighest mean annual costCause inpatient admissionsChronic hepatitis BDisease statesHealthcare resource utilizationLiver disease groupEmergency department utilizationEmergency room visitsHepatocellular carcinoma groupProgressive disease statesPharmaceutical utilizationMean annual costLiver disease statesProgressive diseaseHepatitis B.An expert consensus for the management of chronic hepatitis B in Asian Americans
Tong MJ, Pan CQ, Han S, Lu D, Raman S, Hu K, Lim JK, Hann HW, Min AD. An expert consensus for the management of chronic hepatitis B in Asian Americans. Alimentary Pharmacology & Therapeutics 2018, 47: 1181-1200. PMID: 29479728, PMCID: PMC5900913, DOI: 10.1111/apt.14577.Peer-Reviewed Original ResearchConceptsChronic hepatitis BAnti-viral therapyHepatocellular carcinomaHepatitis BHBV DNAPregnant womenBasal core promoter mutationsNegative chronic hepatitis BHepatitis B virus infectionAsian American physiciansLiver related deathManagement of HBVDetectable HBV DNAHBeAg-negative patientsHBsAg-positive patientsHBV DNA levelsNormal ALT levelsB virus infectionCore promoter mutationsHBsAg carrier rateLife-long surveillanceContrast CT scanAbdominal ultrasound examinationAlpha-fetoprotein testingAsian American patients